{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:07:03Z","timestamp":1782889623924,"version":"3.54.5"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T00:00:00Z","timestamp":1539129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Barcelona\u2019s Professional Pharmacist Association"},{"name":"Fundaci\u00f3n Jos\u00e9 Luis Casta\u00f1o (FENIN scholarship 2014)"},{"name":"Fundaci\u00f3 Parc Taul\u00ed Institut Universitari UAB (Parc Taul\u00ed Recerca scholarship 2012)"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0205430","type":"journal-article","created":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T18:37:43Z","timestamp":1539196663000},"page":"e0205430","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4413-1593","authenticated-orcid":true,"given":"Cristina","family":"Ruiz-Iruela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Padr\u00f3-Miquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pint\u00f3-Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Baena-D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assumpta","family":"Caix\u00e0s-Pedrag\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"G\u00fcell-Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8312-492X","authenticated-orcid":true,"given":"Rosa","family":"Navarro-Badal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Jusmet-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Calmarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Puzo-Foncilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Al\u00eda-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Cand\u00e1s-Est\u00e9banez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,10,10]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein colesterol reduction: The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial","volume":"5","author":"DI Chasman","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"ref2","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad: National Healthcare system Anual Report, 2016. Available in <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.msssi.gob.es\" xlink:type=\"simple\">www.msssi.gob.es<\/ext-link>."},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pcad.2004.04.007","article-title":"Comparative effects of lipid-lowering therapies","volume":"47","author":"MH Davidson","year":"2004","journal-title":"Progress in Cardiovascular Diseases"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/PGPM.S86013","article-title":"Pharmacogenomics of statins: understanding susceptibility to adverse effects","volume":"9","author":"JP Kitzmiller","year":"2016","journal-title":"Pharmacogenomics and Personalized Medicine"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/phar.1981","article-title":"Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia","volume":"37","author":"WD Maxwell","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref6","first-page":"15","article-title":"Seventeen years of statin pharmacogenetics: a systematic review","volume":"17","author":"M Leusink","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e50126","DOI":"10.1371\/journal.pone.0050126","article-title":"Meta-Analyses of KIF6 Trp719Arg in Coronary Heart Disease and Statin Therapeutic Effect","author":"P Peng","year":"2012","journal-title":"PLoS ONE"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.amjcard.2010.05.033","article-title":"KIF6 Polymorphism as a Predictor of Risk of Coronary Events and of Clinical Event Reduction by Statin Therapy","volume":"106","author":"Y Li","year":"2010","journal-title":"American Journal of Cardiology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00439-010-0892-6","article-title":"Genetic variants in the KIF6 region and coronary event reduction from statin therapy","volume":"129","author":"Y Li","year":"2011","journal-title":"Human Genetics"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacc.2007.05.057","article-title":"Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials","volume":"51","author":"OA Iakoubova","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.amjcard.2009.12.049","article-title":"Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial","volume":"105","author":"D Shiffman","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/HJR.0b013e328336a0dd","article-title":"KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study by in European journal of cardiovascular prevention and rehabilitation","volume":"17","author":"OA Iakoubova","year":"2010","journal-title":"European Journal of Preventive Cardiology"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jacc.2007.10.017","article-title":"Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study","volume":"51","author":"OA Iakoubova","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12944-017-0651-y","article-title":"Association between KIF6 rs20455 polymorphism and the risk of coronary heart disease (CHD): a pooled analysis of 50 individual studies including 40,059 cases and 64,032 controls","volume":"17","author":"Y Li","year":"2018","journal-title":"Lipids Health Disease"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5144\/0256-4947.2016.21.3.1140","article-title":"Investigation of KIF6 Trp719Arg gene polymorphism in a case-control study of coronary artery disease and non-fatal myocardial infarction in the Eastern Province of Saudi Arabia","volume":"36","author":"C Vatte","year":"2016","journal-title":"Annals of Saudi Medicine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cca.2016.01.005","article-title":"Gene variants at FTO, 9p21, and 2q36.3 are age-independently associated with myocardial infarction in Czech men","volume":"454","author":"JA Hubacek","year":"2016","journal-title":"Clinica Chimica Acta"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/CIRCGENETICS.111.960955","article-title":"Lack of Association of KIF6 Genotype with Vascular Disease and Statin Response","volume":"4","author":"K Musunuru","year":"2011","journal-title":"Cardiovascular Genetics"},{"key":"ref18"},{"key":"ref19","article-title":"ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults","author":"NJ Stone","year":"2013","journal-title":"ACC\/AHA Blood Cholesterol Guideline"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Position paper. Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"M Banach","year":"2015","journal-title":"Archives of Medical Science"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/clpt.2014.125","article-title":"The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update","volume":"96","author":"LB Ramsey","year":"2014","journal-title":"Clinical pharmacology and therapeutics"},{"key":"ref22","article-title":"ACC\/AHA Release Updated Guideline on the Treatment of Blood Cholesterol to Reduce ASCVD Risk","year":"2014","journal-title":"American Family Physician"},{"key":"ref23","first-page":"1","article-title":"Satins treatment under the umbrella of pharmacogenetics","volume":"9","author":"V Kolovou","year":"2015","journal-title":"Health Science Journal"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"e976","DOI":"10.1371\/journal.pone.0009763","article-title":"Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study Populations","volume":"5","author":"MJ Barber","year":"2010","journal-title":"PLoS ONE"},{"issue":"86","key":"ref25","first-page":"45","article-title":"Statin pharmacogenomics: Pursuing biomarkers for predicting clinical outcomes","volume":"16","author":"JP Kitzmiller","year":"2013","journal-title":"Discovery Medicine"},{"key":"ref26"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"e38240","DOI":"10.1371\/journal.pone.0038240","article-title":"Genome-Wide Study of Gene Variants Associated with Differential Cardiovascular Event Reduction by Pravastatin Therapy","volume":"7","author":"D Shiffman","year":"2012","journal-title":"PLoS ONE"},{"issue":"20","key":"ref28","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.jacc.2011.02.015","article-title":"No impact of KIF6 Genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study","volume":"57","author":"J Hopewell","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCGENETICS.110.959353","article-title":"Kinesin-Like Protein 6 (KIF6) Polymorphism and the Efficacy of Rosuvastatin in Primary Prevention","volume":"4","author":"PM Ridker","year":"2011","journal-title":"Circulation Cardiovascular Genetics"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCGENETICS.111.960252","article-title":"The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies","volume":"5","author":"BJ Arsenault","year":"2012","journal-title":"Circulation Cardiovascular Genetics"},{"key":"ref31","article-title":"Impact of the 719Arg variant of KIF6 and major cardiovascular events on patients who received statins: a systematic review and meta-analysis","author":"S Chen","year":"2018","journal-title":"Current pharmaceutical design"},{"issue":"Suppl 1","key":"ref32","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1097\/01.hjh.0000467361.35205.0a","article-title":"1a.11: Association of KIF6 and HMGCR loci with cardiometabolic phenotypes and response to statin therapy in the brisighella cohort","volume":"33","author":"M Rosticci","year":"2015","journal-title":"Journal of Hypertension"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010049","article-title":"Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population","volume":"19","author":"S Angelini","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"key":"ref34","article-title":"Expert Panel onDetection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41065-015-0004-7","article-title":"The Trp719Arg polymorphism of the KIF6 gene and coronary heart disease risk: systematic review and meta-analysis","volume":"152","author":"D Ruiz-Ramos","year":"2015","journal-title":"Hereditas"},{"issue":"10","key":"ref36","first-page":"683","article-title":"Impact of KIF6 Polymorphism rs20455 on Coronary Heart Disease Risk and Effectiveness of Statin Therapy in 100 Patients from Southern Iran","volume":"18","author":"L Hamidizadeh","year":"2015","journal-title":"Archives of Iranian medicine"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.12945\/j.aorta.2016.16.003","article-title":"KIF6 719Arg Genetic Variant and Risk for Thoracic Aortic Dissection","volume":"4","author":"OA Iakoubova","year":"2016","journal-title":"AORTA (Stamford)"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"45F","DOI":"10.1016\/j.amjcard.2005.06.026","article-title":"The case for intensive statin therapy after acute coronary syndromes","volume":"96","author":"GG Schwartz","year":"2005","journal-title":"American Journal of Cardiology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"II42","DOI":"10.1161\/01.CIR.0000129500.29229.92","article-title":"Beyond the laboratory: clinical implications for statin pleiotropy","volume":"109","author":"JP Halcox","year":"2004","journal-title":"Circulation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0205430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T10:47:45Z","timestamp":1589021265000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0205430"}},"subtitle":[],"editor":[{"given":"Ying-Mei","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,10]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0205430","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,10]]}}}